Charles River Laboratories International Inc

More Details of Charles River Laboratories International Inc Company

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Company Info

Company codeCRL

Company nameCharles River Laboratories International Inc

IPO dateJun 23, 2000

Founded at1994

CEOMr James C. Foster

Number of employees18600

Security typeOrdinary Share

Fiscal year-endJun 23

Address251 Ballardvale St

CityWILMINGTON

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code01887

Phone17812226000

Websitehttps://www.criver.com/

Company codeCRL

IPO dateJun 23, 2000

Founded at1994

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

250.71K

+1.11%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

46.41K

-3.11%

Mr. Robert J. (Bob) Bertolini, CPA

Independent Director

32.80K

--

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

12.03K

-27.10%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

8.38K

-4.21%

Dr. Deborah Turner Kochevar, Ph.D.

Independent Director

7.89K

--

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

7.60K

+20.39%

Mr. George E. Massaro, CPA

Independent Director

5.86K

--

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

3.96K

--

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

3.02K

--

Name

Name/Position

Position

Shareholding

Change

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

250.71K

+1.11%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

46.41K

-3.11%

Mr. Robert J. (Bob) Bertolini, CPA

Independent Director

32.80K

--

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

12.03K

-27.10%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

8.38K

-4.21%

Dr. Deborah Turner Kochevar, Ph.D.

Independent Director

7.89K

--

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

By BusinessUSD

Name

Revenue

Proportion

DSA

2.45B

60.53%

RMS

829.38M

20.48%

Manufacturing

769.33M

19.00%

By RegionUSD

Name

Revenue

Proportion

United States

2.24B

55.31%

Europe

1.08B

26.62%

Canada

482.09M

11.90%

Asia Pacific (Region)

196.95M

4.86%

Other

52.82M

1.30%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

DSA

2.45B

60.53%

RMS

829.38M

20.48%

Manufacturing

769.33M

19.00%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

12.49%

Wellington Management Company, LLP

8.30%

BlackRock Institutional Trust Company, N.A.

6.01%

State Street Global Advisors (US)

4.44%

Kayne Anderson Rudnick Investment Management, LLC

3.68%

Other

65.09%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

12.49%

Wellington Management Company, LLP

8.30%

BlackRock Institutional Trust Company, N.A.

6.01%

State Street Global Advisors (US)

4.44%

Kayne Anderson Rudnick Investment Management, LLC

3.68%

Other

65.09%

Type

Shareholder

Proportion

Investment Advisor/Hedge Fund

51.46%

Investment Advisor

38.17%

Hedge Fund

12.50%

Research Firm

4.87%

Pension Fund

1.56%

Bank and Trust

1.37%

Sovereign Wealth Fund

1.16%

Individual Investor

0.91%

Insurance Company

0.07%

Institutional Shareholding

Update time: Mon, Jan 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

1401

55.37M

112.71%

-2.95M

2024Q4

1423

54.85M

107.26%

-4.35M

2024Q3

1392

53.78M

105.14%

-5.12M

2024Q2

1399

54.00M

104.84%

-4.00M

2024Q1

1393

53.76M

104.37%

-4.04M

2023Q4

1424

53.56M

104.42%

-4.24M

2023Q3

1446

53.56M

104.42%

-3.98M

2023Q2

1427

52.88M

103.32%

-3.95M

2023Q1

1431

52.72M

103.01%

-2.79M

2022Q4

1416

51.28M

100.65%

-3.46M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

6.13M

12.49%

+58.13K

+0.96%

Dec 31, 2024

Wellington Management Company, LLP

4.08M

8.3%

+335.66K

+8.97%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

2.95M

6.01%

-51.78K

-1.72%

Dec 31, 2024

State Street Global Advisors (US)

2.18M

4.44%

+51.15K

+2.40%

Dec 31, 2024

Kayne Anderson Rudnick Investment Management, LLC

1.81M

3.68%

-134.28K

-6.92%

Dec 31, 2024

Allspring Global Investments, LLC

1.81M

3.68%

+47.22K

+2.68%

Dec 31, 2024

Geode Capital Management, L.L.C.

1.23M

2.51%

+14.79K

+1.21%

Dec 31, 2024

Impactive Capital LP

1.20M

2.45%

+825.95K

+219.44%

Dec 31, 2024

Meritage Group LP

1.07M

2.19%

-111.05K

-9.37%

Dec 31, 2024

Ariel Investments, LLC

1.07M

2.17%

+169.64K

+18.90%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

First Trust NASDAQ Pharmaceuticals ETF

2.3%

Janus Henderson Small/Mid Cap Growth Alpha ETF

2.1%

Schwab Ariel ESG ETF

1.64%

First Trust Health Care Alphadex Fund

1.55%

VanEck Biotech ETF

1.44%

Invesco S&P 500 Equal Weight Health Care ETF

1.35%

ROBO Global Healthcare Technology & Innovation ETF

1.34%

Franklin Genomic Advancements ETF

1.25%

Hilton Small-MidCap Opportunity ETF

1.07%

Amplify AI Powered Equity ETF

1.02%

First Trust NASDAQ Pharmaceuticals ETF

Proportion2.3%

Janus Henderson Small/Mid Cap Growth Alpha ETF

Proportion2.1%

Schwab Ariel ESG ETF

Proportion1.64%

First Trust Health Care Alphadex Fund

Proportion1.55%

VanEck Biotech ETF

Proportion1.44%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion1.35%

ROBO Global Healthcare Technology & Innovation ETF

Proportion1.34%

Franklin Genomic Advancements ETF

Proportion1.25%

Hilton Small-MidCap Opportunity ETF

Proportion1.07%

Amplify AI Powered Equity ETF

Proportion1.02%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

118.610USD

Charles River Laboratories International Inc

118.610

Overview

Company